TrianglePembrolizumab + Single-Agent… (NCT04297605)
Pembrolizumab + Single-Agent Chemotherapy trial for Locally Advanced or Metastatic Non-Small Cell Lung Cancer (ECOG 2) (NCT04297605). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for locally advanced or metastatic non-small cell lung cancer, in adults whose daily activity is limited, called performance status 2.
The idea: pair immunotherapy with a single chemotherapy drug. Pembrolizumab is given with either pemetrexed or nab-paclitaxel, every 21 days, as first treatment. The study enrolls patients with stage three C or stage four disease.
This pilot phase 1 study asks whether the combination is tolerable, and plans 60 patients. At the University of Rochester in New York, Megan Baumgart leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.